You are now searching through our whole database. To make more specific queries, you can use our menu or go directly to papers, companies, trials, or events.
This observational study (n=343) of terrorist attack survivors found that those under the influence of classic psychedelics during the traumatic event reported lower anxiety and post-traumatic symptoms compared to MDMA users or non-users, particularly when psychedelics were taken alone.
This randomised, triple-blind, placebo-controlled Phase I crossover trial (n=24) will compare the acute effects of two enantiomers of MDMA—R-MDMA (300mg) and S-MDMA (100mg)—in healthy adult participants.
This open-label, single-arm Phase I trial (n=20) will study the effects of a single 10 mg oral dose of psilocybin on neural activity, pain, and cognition in adults with chronic pain who have implanted brain-sensing deep brain stimulation (DBS) devices.
This open-label Phase II trial (n=100) will study the safety, tolerability, and potential therapeutic effects of psilocybin (2 x 25 mg oral doses, taken at least 3 weeks apart) in the biological children of genocide survivors who are living with mood and anxiety disorders.
This randomised, quadruple-blind, placebo-controlled Phase I/II trial (n=50) will investigate the antidepressant, psychedelic, and adverse effects of Psilocybe cubensis mushrooms (equivalent to 30 mg of psilocybin) with or without daily fluoxetine (20mg) in adults with treatment-resistant depression.
This open-label, single-arm early Phase I trial (n=20) will assess the feasibility, tolerability, and potential effectiveness of a single 25 mg dose of psilocybin in promoting abstinence from methamphetamine in adults undergoing residential addiction treatment.
This randomised, placebo-controlled, triple-blind Phase I crossover trial (n=24) will compare the acute and subacute effects of LSD (150µg), psilocybin (30mg), and DMT (up to 2 mg/min intravenous infusion) in healthy adults, with all sessions standardised using ketanserin (20 mg IV) to end the psychedelic experience after three hours.
This Phase II, open-label trial (n=35) will study the efficacy, safety, and tolerability of psilocybin (25mg) combined with therapy in women with post-traumatic stress disorder (PTSD) stemming from sexual assault.
This open-label, Phase II/III trial (n=36) will study the effects of ketamine (35mg/70kg via intravenous infusion) on suicidal ideation in individuals with major depressive disorder (MDD).
This randomised, placebo-controlled, quadruple-masked trial (n=112) will investigate whether the antidepressant effects of DMT (2 mg/min over 20 minutes) in patients with major depressive disorder (MDD) depend on the subjective psychedelic experience, by comparing DMT with and without sedation using propofol.
Psychedelic Database
Find everything on psychedelics as medicine. This page allows you to search through our whole database, from research papers to news articles, and from clinical trials to academic articles.
Next to our databases, don’t forget to check out our reports. The reports bring together the separate pieces of information from our database entries into written reports.
